An Extension Study to Assess the Long-Term Safety, Tolerability, Pharmacokinetics, and Effect on Disease Progression of BIIB078 Administered to Previously Treated Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis
Latest Information Update: 03 Feb 2023
At a glance
- Drugs Tadnersen (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions
- Sponsors Biogen
Most Recent Events
- 31 Jan 2023 According to ClinicalTrials.gov record, protocol has been amended as treatment arm changed from 3 to 4
- 28 Mar 2022 Status changed from active, no longer recruiting to discontinued, according to Biogen media release.
- 21 Feb 2022 Status changed from recruiting to active, no longer recruiting.